(NASDAQ: CGC) Canopy Growth's forecast annual revenue growth rate of 17.77% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Canopy Growth's revenue in 2025 is $199,006,428.On average, 7 Wall Street analysts forecast CGC's revenue for 2026 to be $98,295,788,361, with the lowest CGC revenue forecast at $92,824,075,025, and the highest CGC revenue forecast at $102,583,503,690. On average, 6 Wall Street analysts forecast CGC's revenue for 2027 to be $105,505,857,154, with the lowest CGC revenue forecast at $99,264,202,916, and the highest CGC revenue forecast at $113,567,993,877.
In 2028, CGC is forecast to generate $110,611,420,817 in revenue, with the lowest revenue forecast at $106,272,376,095 and the highest revenue forecast at $113,865,704,359.